SCHEMBL6322186

SCHEMBL6322186

Nc1onc(-c2ccc(Cl)s2)c1C(=O)NC1CCC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
CA4 P22748 1/20 0.57
CA7 P43166 1/20 0.57
KMT2A Q03164 4/20 0.44
TP53 P04637 3/20 0.44
MDM2 Q00987 3/20 0.44
RAB9A P51151 8/20 0.41
NPC1 O15118 7/20 0.41
TRPV1 Q8NER1 2/20 0.41
MEN1 O00255 3/20 0.40
F10 P00742 4/20 0.40
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MLLT3 P42568 1/20 0.39
MLLT1 Q03111 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323501 0.98 CA1 (0.57) CA1CA2CA4CA7KMT2A
SCHEMBL6317453 0.97 CA1 (0.56) CA1CA2CA4CA7KMT2A
SCHEMBL6323378 0.97 CA1 (0.56) CA1CA2CA4CA7KMT2A
SCHEMBL6323607 0.87 KMT2A (0.45) CA1CA2CA4CA7KMT2A
SCHEMBL6324536 0.86 ALDH1A1 (0.48) CA1CA2CA4CA7KMT2A
SCHEMBL6317383 0.85 KMT2A (0.47) CA1CA2CA4CA7KMT2A
SCHEMBL6315351 0.84 NPC1 (0.51) CA1CA2CA4CA7KMT2A
SCHEMBL6317748 0.84 KMT2A (0.49) CA1CA2CA4CA7KMT2A
SCHEMBL6321143 0.84 HPGD (0.51) CA1CA2CA4CA7KMT2A
SCHEMBL6323035 0.84 KMT2A (0.49) CA1CA2CA4CA7KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 CA1 2406/4885CA2 2764/4885CA4 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.